Upadacitinib (new indication: ulcerative colitis, pretreated patients)

Subject:

• Active Sustance: Upadacitinib
• Name: Rinvoq®
• Therapeutic area: Ulcerative colitis
• Pharmaceutical company: AbbVie Deutschland GmbH & Co. KG

Time table:

• Start: 01.09.2022
• Final decision by G-BA: 16.02.2023

Final decision:

1. Patients, who have had an inadequate response, no longer respond to conventional therapy, or have an intolerance or contraindication: No additional benefit proved
2. Patients, who have had an inadequate response, no longer respond, or are intolerant to a biologic (TNF-α antagonist or integrin inhibitor or interleukin inhibitor): No additional benefit proved